Transcera

Boston, US · 2 known investors

Transcera is a biotech company developing a new class of therapeutics that use lipid trafficking pathways to direct extracellular proteins into lysosomes for degradation, aimed at treating chronic diseases. Its platform combines a lysosome-targeting lipid, a chemical linker, and a peptide or protein binder to degrade soluble and membrane proteins across tissues.